Nancy Dumont, Ph.D.
Affiliations: | 2002 | Vanderbilt University, Nashville, TN |
Area:
Cell Biology, Oncology, Molecular BiologyGoogle:
"Nancy Dumont"Parents
Sign in to add mentor| Carlos L. Arteaga | grad student | 2002 | Vanderbilt | |
| (The role of autocrine transforming growth factor beta signaling in breast cancer progression.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cervia LD, Shibue T, Borah AA, et al. (2022) A ubiquitination cascade regulating the integrated stress response and survival in carcinomas. Cancer Discovery |
| Neggers JE, Paolella BR, Asfaw A, et al. (2020) Abstract LB-053: VPS4A is a synthetic lethal target in VPS4B-deficient cancers due to co-deletion with SMAD4 Cancer Research. 80 |
| Corsello SM, Spangler RD, Humeidi R, et al. (2020) Abstract 3400: Adenosine receptor antagonists exhibit potent and selective off-target killing of FOXA1-high cancers Tumor Biology |
| Sulahian R, Kwon JJ, Walsh KH, et al. (2019) Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers. Cell Reports. 29: 118-134.e8 |
| Chan EM, Shibue T, McFarland JM, et al. (2019) WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature |
| Kamoun WS, Kirpotin DB, Huang ZR, et al. (2019) Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature Biomedical Engineering. 3: 264-280 |
| Dumont N, Merrigan S, Turpin J, et al. (2019) Nanoliposome targeting in breast Cancer is influenced by the tumor microenvironment. Nanomedicine : Nanotechnology, Biology, and Medicine |
| Corsello SM, Spangler RD, Nagari RT, et al. (2019) Abstract 2948: Novel cell line barcoding method reveals tepoxalin as a selective drug against MDR1-high tumor cells Cancer Research |
| Geretti E, Espelin C, Adiwijaya B, et al. (2017) Abstract P4-21-40: In vitro and in vivo activity of HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 in HER2-intermediate tumors Cancer Research. 77 |
| Geretti E, Espelin C, Adiwijaya B, et al. (2016) Abstract LB-061: HER2-targeted PEGylated liposomal doxorubicin (MM-302) efficiently targets the HER2 intermediate cell population in vitro and in vivo Cancer Research. 76 |